The Effect of Total Cholesterol Variability on Clinical Outcomes After Percutaneous Coronary Intervention

Yanting Liang, Haochen Wang, Fengyao Liu, Xueju Yu, Yan Liang, Han Yin, Yuting Liu, Cheng Jiang, Yu Wang, Bingqing Bai, Anbang Liu, Xiaobe Shi, Weiya Li, Quanjun Liu, Yilin Chen, Lan Guo, Huan Ma and Qingshan Geng

1 Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 2 Department of Geriatrics, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 3 School of Medicine, South China University of Technology, Guangzhou, China

Aim: Exploring the risk factors of prognosis in patients undergoing percutaneous coronary intervention (PCI) is of great importance. Our aim of the study is to investigate the association between variability in total cholesterol (TC) level and major adverse cardiovascular and cerebrovascular events (MACCE) in patients after PCI.

Methods: Between April 2004 and December 2009, 909 patients who underwent primary PCI and with at least three TC values were included in the final study. TC variability was calculated using four indices: standard deviation (SD), coefficient of variation (CV), the average successive variability (ASV), variability independent of the mean (VIM). MACCE comprised all-cause mortality, non-fatal myocardial infarction (MI), unplanned revascularization, hospitalization for heart failure, and non-fatal stroke.

Results: There were 394 cases of MACCE during the follow-up period. When the subjects were divided into quartile groups by CV of TC, high CV groups were associated with a higher hazard ratio of MACCE than for lower CV groups. In multivariable adjusted models, TC variability and MACCE remained correlated [HR (95% CI): Q2, 1.17 (0.86–1.58); Q3, 1.38 (1.03–1.85); Q4, 1.63 (1.22–2.17)]. Similar patterns of MACCE were noted by quartiles of SD, ASV, and VIM.

Conclusion: Visit-to-visit TC variability is positively correlated with MACCE in patients after PCI.

Keywords: total cholesterol variability, coronary artery disease, percutaneous coronary intervention, clinical outcomes, major adverse cardiovascular, cerebrovascular events
Abnormal blood lipid metabolism is a risk factor for CAD (8). It has been well-established that high concentrations of total cholesterol (TC) are associated with greater CAD risk. Serum total cholesterol contribute to atherosclerosis and fluctuations of blood cholesterol level may be independently associated with adverse outcomes (9, 10). Therefore, monitoring and management blood lipid after PCI is essential.

Recently, the visit-to-visit cholesterol variability is under the spotlight. A high visit-to-visit variability in cholesterol levels was suggested to be an independent predictor of major adverse cardiovascular events (MACE) (11). A previous study showed that the visit-to-visit variability in fasting measurements of high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) are predictive of coronary events (12). A study demonstrated that, for general population, total cholesterol (TC) variability is a vital risk factor (11). Another study suggested that the visit-to-visit variability in LDL-C, HDL-C, and non-HDL-C in post-PCI patients can be considered as a predictor of adverse cardiovascular events (13). However, few previous studies have directly assessed the role of TC variability as a predictor of MACCE among post-PCI patients. Therefore, we sought to evaluate the prognostic impact of TC variability in patients undergoing PCI.

METHODS

Research was carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the Guangdong Provincial People's Hospital Ethics Committee. Written consents were obtained from participating patients.

Patients

In this study, we recruited patients from “CHD club” of Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital. Subjects were those CHD patients who have had PCI between April 2004 and December 2009. CHD secondary prevention educations were provided to patients by a regular doctor in the “CHD club,” which include lifestyle adjustment instructions and drug treatments. Biochemical investigations were also conducted during hospitalization and 1, 3, 6, 12, 24, and 36 months after PCI. All blood lipid measurements were carried out in the same testing institution to avoid bias caused by different measuring instruments. Among the 2,258 patients enrolled in this club, 909 patients with at least three TC values were included in the final study. Baseline data was collected from the time of PCI.

PCI and Medications

PCI was performed by experienced interventional cardiologists according to standard national practice as described in previous researches (14). The use of statins, antiplatelet agents (aspirin/clopidogrel), β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, diuretics, or inotropic drugs was based on the discretion of the attending cardiologist according to clinical protocol derived from national interventional guidelines.

Variability Measurements

TC values were measured during hospitalization and 1, 3, 6, 12, 24, and 36 months after PCI. In this study, patients completing the baseline TC values and at least 2 post-baseline TC values were included in analyses. TC variability was defined as intra-individual variability in TC values between visits. Four indices of variability were used: (1) standard deviation (SD), (2) coefficient of variation (CV), (3) the average successive variability (ASV), which refers to the average absolute difference between successive values, (4) variability independent of the mean (VIM), which was calculated as $100 \times SD/\text{Mean}^{\beta}$, where beta is the regression coefficient, on the basis of natural logarithm of SD on the natural logarithm of mean (15). The mean of TC measurements is 4.64 and the number of TC measurements per patient ranged from 3 to 7: 3 measurements ($n = 247, 27.2\%$), 4 measurements ($n = 221, 24.3\%$), 5 measurements ($n = 177, 19.5\%$), and 6 measurements ($n = 139, 15.3\%$), 6 measurements ($n = 139, 14.3\%$), and 7 measurements ($n = 125, 13.8\%$).

Clinical Outcomes and Follow-Up

Annual telephone follow-up was conducted by trained research assistants for all participants according to standardized protocols, which guaranteed the reliability of the survey. The endpoint of the study was the major adverse cardiovascular and cerebrovascular events (MACCE). Components of MACCE included all-cause mortality, myocardial infarction (MI), unplanned revascularization, hospitalization for heart failure, and non-fatal stroke.

Statistical Analysis

We categorized subjects into four groups according to the quartile distribution of TC variability. The Kaplan-Meier curves was used to analyze survival and disease-free probability, and the log-rank test was performed to analyze the significance of the difference between groups. The Cox proportional hazards regression model was performed to calculate the 95% confidence interval (95% CI) and hazard ratios (HR) values of different outcomes. Three multivariable models were conducted: in Model one, age, sex, BMI, and smoking history were adjusted; Model two was adjusted for the variables in model one plus diabetes and hypertension; Model three was adjusted for the variables in model two plus mean TC value and lipid-lowering agents. Sensitivity analyses were also performed. Statistical analyses were performed using SPSS (IBM SPSS 26.0, SPSS Inc). A $P < 0.05$ was considered statistically significant.

RESULTS

Baseline Characteristics of Participants

Follow-up ranged from 48 to 59 months (median follow-up, 53 months). Table 1 shows characteristics of subjects according to CV quartiles. Subjects with higher TC variability were more likely to have dyslipidaemia and need to use lipid-lowering agents more frequently. These patients were more frequently atorvastatin treatment. There were no statistically significant differences of mean TC level between groups ($4.5 \pm 0.9 \text{mmol/L}$). The CV values of TC in the Q1-Q4 groups were $6.1\%$, $5.5\%$, $5.9\%$, and $6.6\%$.
± 1.3, 16.8 ± 1.7, and 25.9 ± 5.5%, respectively. We found that there is no significant difference in the first TC measurement months after PCI between quartiles. The first TC measurement of the included patients usually measured in 1 months after PCI (Supplementary Table S6). For details of baseline characteristics according to quartiles of SD, ASV and VIM, see Supplementary Materials (Supplementary Tables S1–3).

Visit-to-Visit TC Variability and MACCE
There were 394 cases of MACCE during the follow-up period. When the subjects were divided into quartile groups by CV of TC, high CV groups were associated with a higher hazard ratio of MACCE than the lower CV groups. TC variability and MACCE still remained correlated in Model 4 [HR (95% CI): Q2, 1.17 (0.86–1.58); Q3, 1.38 (1.03–1.85); Q4, 1.63 (1.22–2.17)]. Similar patterns of MACCE were noted by quartiles of SD, ASV and VIM. An additive effect of the variability of TC on the risk of MACCE was identified (Table 2). The Kaplan-Meier cumulative MACCE-free survival curves by quartiles of TC variability measured as different indices showed that the presence of high variability of TC was associated with higher incidences of MACCE after PCI (Figure 1).

### Sensitivity Analysis
Findings were similar when SD, ASV, and VIM were used to determine the variability of TC. Even after full multivariable adjustment, TC variability as measured by SD, ASV, or VIM was also an independent predictor of MACCE (Table 2, Figure 1). The relation between TC variability and MACCE still remained significant when excluding subjects with dyslipidaemia (see Supplementary Material, Supplementary Table S4). Furthermore, we performed time-dependent Cox regression analysis. Similar results were observed when using the mean TC value as time-varying covariates (see Supplementary Materials online, Supplementary Table S5).

### DISCUSSION
To our knowledge, this is the first study reporting the relationship between visit-to-visit TC variability and long-term cardiovascular outcomes in patients with previous PCI. In this study, we demonstrated that TC variability was significantly associated with increased risk for MACCE in patients with previous PCI, even after adjustment for age, sex, BMI, smoking history, diabetes, hypertension, and lipid-lowering agents. The results remained significant when use other indices of TC variability and by several sensitivity analyses. The relationship between TC variability and MACCE still remained significant when subjects with dyslipidaemia were excluded. Therefore, it is important to monitor variability in cholesterol levels among post-PCI patients without dyslipidaemia. This finding indicates that visit-to-visit TC variability may be novel biometrics for monitoring response to lipid-lowering therapy and a predictor of MACCE in post-PCI patients.

---

### TABLE 1 | Baseline characteristics of subjects to the total cholesterol variability (coefficient of variation).

|                | Q 1 (n = 228) | Q 2 (n = 227) | Q 3 (n = 227) | Q 4 (n = 227) | Overall (n = 909) | P-value |
|----------------|---------------|---------------|---------------|---------------|------------------|---------|
| Age (years)    | 64.2 ± 10     | 64.2 ± 10.4   | 63.6 ± 9.2    | 61.9 ± 10.9   | 63.5 ± 10.2      | 0.077   |
| Sex (male)     | 164 (71.9)    | 176 (78.4)    | 179 (75.9)    | 171 (75.3)    | 692 (76.1)       | 0.276   |
| Body mass index (kg/m²) | 23.9 ± 2.9     | 23.9 ± 2.9    | 24 ± 3.2      | 24.2 ± 3.3    | 24 ± 3           | 0.598   |
| Mean TC (mmol/L) | 4.4 ± 0.8     | 4.4 ± 0.9     | 4.5 ± 0.8     | 4.5 ± 0.9     | 4.5 ± 0.9        | 0.617   |
| **TC variability**
| CV (%)         | 6.1 ± 2.4     | 12.1 ± 1.3    | 16.8 ± 1.7    | 25.9 ± 5.5    | 15.2 ± 7.9       | < 0.001 |
| SD (mmol/L)    | 0.3 ± 0.1     | 0.5 ± 0.1     | 0.8 ± 0.2     | 1.2 ± 0.4     | 0.7 ± 0.4        | < 0.001 |
| ASV (mmol/L)   | 0.3 ± 0.2     | 0.6 ± 0.2     | 0.8 ± 0.3     | 1.3 ± 0.6     | 0.7 ± 0.5        | < 0.001 |
| VIM (%)        | 4.5 ± 1.8     | 9 ± 1         | 12.5 ± 1.3    | 19.2 ± 4.1    | 11.3 ± 5.9       | < 0.001 |
| Current smoker | 71 (31.1)     | 75 (33)       | 84 (37)       | 80 (35.2)     | 310 (34.1)       | 0.575   |
| Hypertension   | 200 (87.7)    | 208 (91.6)    | 198 (87.2)    | 195 (85.9)    | 801 (88.1)       | 0.267   |
| Diabetes mellitus | 51 (22.4)    | 50 (22)       | 62 (27.3)     | 64 (28.2)     | 227 (25)         | 0.284   |
| Dyslipidaemia  | 44 (19.3)     | 59 (26)       | 79 (34.8)     | 106 (46.7)    | 288 (31.7)       | < 0.001 |
| On lipid-lowering agent | 160 (70.2) | 190 (83.7) | 187 (82.4) | 180 (79.3) | 717 (78.9) | 0.002 |
| **Lipid-lowering agent type**
| Atorvastatin  | 73 (45.3)     | 99 (52.4)     | 101 (54.3)    | 105 (58)      | 378 (42.7)       | –       |
| Simvastatin   | 57 (35.4)     | 64 (33.9)     | 49 (26.3)     | 54 (29.8)     | 224 (24.1)       | –       |
| Pravastatin   | 11 (6.8)      | 14 (7.4)      | 12 (6.5)      | 7 (3.9)       | 44 (6.1)         | –       |
| Fluvastatin   | 15 (9.3)      | 6 (3.2)       | 15 (8.1)      | 10 (5.5)      | 46 (6.4)         | –       |
| Other         | 5 (3.1)       | 6 (3.2)       | 9 (4.8)       | 5 (2.8)       | 25 (3.5)         | –       |
| The first TC measurement months after PCI | 1.9 ± 1.2 | 1.7 ± 1.0 | 1.8 ± 1.1 | 1.9 ± 1.1 | 1.8 ± 1.1 | 0.212 |

Data are expressed as the mean ± SD, or n (%).
TC, total cholesterol; CV, coefficient of variation; SD, standard deviation; ASV, the average successive variability; VIM, variability independent of the mean.
TABLE 2 | Hazard ratios and 95% confidence intervals of MACCE by quartiles of total cholesterol variability.

| Events | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
|--------|------------|---------|------------|---------|------------|---------|------------|---------|
| CV     |            |         |            |         |            |         |            |         |
| Q 1    | 1 (ref)    | 0.003   | 1 (ref)    | 0.003   | 1 (ref)    | 0.003   | 1 (ref)    | 0.005   |
| Q 2    | 1.22 (0.90–1.64) | 0.204  | 1.20 (0.89–1.62) | 0.242  | 1.20 (0.89–1.62) | 0.242  | 1.17 (0.86–1.58) | 0.316  |
| Q 3    | 1.43 (1.07–1.91) | 0.017  | 1.40 (1.05–1.88) | 0.024  | 1.40 (1.05–1.88) | 0.024  | 1.38 (1.03–1.85) | 0.354  |
| Q 4    | 1.68 (1.26–2.23) | < 0.001 | 1.67 (1.25–2.22) | < 0.001 | 1.67 (1.25–2.22) | < 0.001 | 1.63 (1.22–2.17) | 0.001  |
| P for trend | 0.003 | 0.011 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| SD     |            |         |            |         |            |         |            |         |
| Q 1    | 1 (ref)    | 0.019   | 1 (ref)    | 0.012   | 1 (ref)    | 0.012   | 1 (ref)    | 0.015   |
| Q 2    | 1.01 (0.75–1.35) | 0.97   | 1 (0.74–1.34) | 0.98   | 1 (0.74–1.34) | 0.98   | 0.98 (0.73–1.31) | 0.875  |
| Q 3    | 1.19 (0.89–1.58) | 0.243  | 1.18 (0.89–1.57) | 0.256  | 1.18 (0.89–1.57) | 0.256  | 1.15 (0.86–1.53) | 0.354  |
| Q 4    | 1.47 (1.11–1.94) | 0.006  | 1.49 (1.13–1.97) | 0.005  | 1.49 (1.13–1.97) | 0.005  | 1.46 (1.11–1.93) | 0.007  |
| P for trend | 0.019 | 0.004 | 0.004 | 0.001 |
| ASV    |            |         |            |         |            |         |            |         |
| Q 1    | 1 (ref)    | 0.012   | 1 (ref)    | 0.008   | 1 (ref)    | 0.008   | 1 (ref)    | 0.015   |
| Q 2    | 1.09 (0.81–1.48) | 0.59   | 1.09 (0.81–1.47) | 0.559  | 1.09 (0.81–1.47) | 0.559  | 1.07 (0.79–1.44) | 0.659  |
| Q 3    | 1.41 (1.06–1.87) | 0.017  | 1.4 (1.06–1.86) | 0.019  | 1.4 (1.06–1.86) | 0.019  | 1.36 (1.03–1.81) | 0.031  |
| Q 4    | 1.48 (1.12–1.96) | 0.006  | 1.53 (1.16–2.03) | 0.003  | 1.53 (1.16–2.03) | 0.003  | 1.49 (1.12–1.97) | 0.006  |
| P for trend | 0.012 | 0.002 | 0.002 | 0.001 |
| VIM    |            |         |            |         |            |         |            |         |
| Q 1    | 1 (ref)    | 0.002   | 1 (ref)    | 0.002   | 1 (ref)    | 0.002   | 1 (ref)    | 0.004   |
| Q 2    | 1.2 (0.89–1.63) | 0.234  | 1.2 (0.89–1.63) | 0.234  | 1.2 (0.89–1.63) | 0.234  | 1.16 (0.86–1.57) | 0.34   |
| Q 3    | 1.54 (1.15–2.06) | 0.004  | 1.54 (1.15–2.06) | 0.004  | 1.54 (1.15–2.06) | 0.004  | 1.49 (1.11–2) | 0.007  |
| Q 4    | 1.65 (1.24–2.21) | 0.001  | 1.65 (1.24–2.21) | 0.001  | 1.65 (1.24–2.21) | 0.001  | 1.6 (1.19–2.13) | 0.002  |
| P for trend | 0.002 | 0.002 | 0.002 | < 0.001 |

Model 1: adjusted for age, sex, body mass index and smoking history.
Model 2: adjusted for model 1 plus diabetes mellitus and hypertension.
Model 3: adjusted for model 2 plus mean total cholesterol level and the use of lipid-lowering agents.
MACCE, the major adverse cardiovascular and cerebrovascular events; HR, hazard ratio; CI, confidence intervals; CV, coefficient of variation; SD, standard deviation; ASV, the average successive variability; VIM, variability independent of the mean.

Acute coronary syndrome (ACS) is one of leading cause of death in the world (16). PCI has tremendous progress on the management of patients with ACS, which dramatically reduces the cardiovascular mortality and disability rates (17, 18). However, there are still life-threatening complications after PCI, such as death, MI and stroke (19). Therefore, it is necessary to identify modifiable risk factors for prognosis in post-PCI patients (20–22).

Variability in biological parameters has been considered as biomarkers with the prognostic value in many studies. Although these parameters are different in mechanisms, these fluctuations in biological indicators such as blood pressure, heart rate, and lipid levels may contribute to and be predictors of clinical outcomes. Visit-to-visit blood pressure variability is studied the most (23–25). In a randomized controlled trial of 13,803 patients with hypertension, the level of visit-to-visit systolic blood pressure variability was reported to be associated with the risk of cardiovascular events (24). Although cholesterol level is considered one of the most contributing risk factors for the prognosis of PCI, the correlation between cholesterol variability and CVD has been little investigated, especially in patients who underwent PCI.

A study with 3,656,648 subjects reported that in the multivariable adjusted model, the HR and 95% CI of CV for all-cause mortality, MI, and stroke were, respectively, 1.26 (1.24–1.28), 1.08 (1.05–1.11), and 1.11 (1.08–1.14) (11). In our study, results shows that in post-PCI patients, the HR and 95% CI for the highest vs. lowest quartiles of CV of TC are 1.63 (1.22–2.17) for MACCE. It indicates that TC variability level may have a greater impact on adverse clinical outcomes in patients after PCI than in the general population. In another study with 1,792 subjects, LDL-, HDL-, and non-HDL-cholesterol variability was demonstrated to be significantly associated with increased risk for MACCE in post-PCI patients (13). Our study finds that the level of TC variability is also an independent predictor of MACCEs in patients who underwent PCI. Further study is required to determine which cholesterol variability is the best.
Limitations
The retrospective single-center design is the main limitation of our study. To overcome this limitation, more rigorous and long-term multicenter studies are needed in the future. Secondly, dosage information of lipid-lowering agents was unavailable. Thirdly, the information about dietary habits and medication compliance was not available. These limitations make it hard for us to analyze the factors contributing to high variability. Lastly, only the Chinese population was included in the study and therefore our results cannot be extrapolated to other ethnicities.

CONCLUSIONS
In conclusion, TC variability is a predictor of MACCE in patients who underwent PCI. The results of this study provide new clinical significance for continuous monitoring of TC levels in patients after PCI. Future studies should explore factors influencing lipid variability and clarify the relationship between interventions to reduce lipid variability and clinical outcomes. The development of long-acting lipid-lowering drugs may be of great help.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Guangdong Provincial People's Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS
YantL, HW, and FL performed and interpreted statistical analysis and drafted manuscript writing. YantL, FL, HW, XY, YanL, HY, YuL, CJ, YW, BB, AL, XS, WL, and YC collected and entered data into database. LG, HM, and QG were senior physicians...
principally responsible for the study. HM and QG revised the paper. All authors read and approved the final manuscript.

FUNDING
This work was supported by the grants of the National Natural Science Foundation of China (Grant No. 8160284), Natural Science Foundation of Guangdong Province (Grant No. 2019A15 15011224), and Traditional Chinese Medicine Bureau of Guangdong Province (Grant 20201008).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.804031/full#supplementary-material

REFERENCES
1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Europ Heart J. (2014) 35:2541–69. doi: 10.1093/eurheartj/ehu278

2. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DESCover Registry. Circulation. (2006) 114:2154–62. doi: 10.1161/CIRCULATIONAHA.106.667915

3. Lin MJ, Chen CY, Lin HD, Wu HP. Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovasc Disord. (2017) 17:12. doi: 10.1186/s12872-016-0454-5

4. Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, et al. Which is the worst risk factor for the long-term clinical outcome? Comparison of long-term clinical outcomes between antecedent hypertension and diabetes mellitus in South Korean acute myocardial infarction patients after stent implantation. J Diabetes. (2020) 12:119–33. doi: 10.1111/1753-0407.12979

5. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. (2015) 66:495–507. doi: 10.1016/j.jacc.2015.05.065

6. Redfors B, Furer A, Selker HP, Thiele H, Patel MR, Chen S, et al. Effect of smoking on outcomes of primary PCI in patients with STEMI. J Am Coll Cardiol. (2020) 75:1743–54. doi: 10.1016/j.jacc.2020.02.045

7. Chandrasekhar J, Zaman S. Associations between C-Reactive protein, obesity, sex, and PCI outcomes: the fat of the matter. JACC Cardiovasc Intervent. (2020) 13:2893–5. doi: 10.1016/j.jcin.2020.10.047

8. Lee J, Chang P, Zhang Y, Kizer J, Best L, Howard B. Triglyceride and HDL-cholesterol variability and the risk of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. Diabetes Care. (2017) 40:529–37. doi: 10.2337/dc16-1958

9. Zhu Y, Lu J, Yu Z, Li D, Wu M, Shen P, et al. Intra-individual variability of total cholesterol is associated with cardiovascular disease mortality: A cohort study. Nutr Metab Cardiovasc Dis. (2019) 29:1205–13. doi: 10.1016/j.numecd.2019.07.007

10. Carroll M, Kit B, Lacher D, Shero S, Mussolino M. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. (2012) 308:1545–54. doi: 10.1001/jama.2012.13260

11. Kim MK, Han K, Kim HS, Park YM, Kwon HS, Yoon KH, et al. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. Eur Heart J. (2017) 38:3560–6. doi: 10.1093/eurheartj/ehx585

12. Waters DD, Bangalore S, Fayyad R, DeMicco DA, Laskey R, Melamed S, et al. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. J Clin Lipidol. (2018) 12:356–66. doi: 10.1016/j.jacl.2017.12.003

13. Lee EY, Yang Y, Kim HS, Cho JH, Yoon KH, Chung WS, et al. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention. Atherosclerosis. (2018) 279:1–9. doi: 10.1016/j.atherosclerosis.2018.10.012

14. Ma H, Liu Y, Xie H, Zhang G, Zhan H, Liu Z, et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational study. Medicine. (2017) 96:e7351. doi: 10.1097/MD.0000000000007351

15. Bangalore S, Breazna A, DeMicco DA, Wan CC, Messerli FH. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol. (2015) 65:1539–48. doi: 10.1016/j.jacc.2015.02.017

16. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. (2013) 127:749–56. doi: 10.1161/CIRCULATIONAHA.112.128413

17. Naito R, Miyauchi K, Konishi H, Tsuoboi S, Ogita M, Dohi T, et al. Comparing mortality between coronary artery bypass grafting and percutaneous coronary intervention with drug-eluting stents in elderly patients with diabetes and multivessel coronary disease. Heart Vessels. (2016) 31:1424–9. doi: 10.1007/s00380-015-0746-1

18. Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. (2004) 364:583–91. doi: 10.1016/S0140-6736(04)6850-5

19. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Europ Heart J. (2009) 30:916–22. doi: 10.1093/eurheartj/ehp41

20. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Europ Heart J. (2013) 34:2444–52. doi: 10.1093/eurheartj/eht412

21. Yin H, Geng Q. Advances in discovering the interrelationship between mental disorders and heart diseases. Heart and Mind. (2017) 1:71–7. doi: 10.4103/hm.hm_14_17

22. Landes U, Kornowski R, Assali A, Vaknin-Assa H, Greenberg G, Lev EI, et al. Predictors of long term outcomes in 11,441 consecutive patients undergoing percutaneous coronary intervention. Am J Cardiol. (2015) 115:855–9. doi: 10.1016/j.amjcard.2015.01.009

23. Diaz KM, Tanner RM, Falzon L, Levitan EB, Reynolds K, Shimbo D, et al. Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension. (2014) 64:965–82. doi: 10.1161/HYPTENSIONAHA.114.039030

24. Mehlum MH, Liestøl K, Kjølseth SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Europ Heart J. (2018) 39:2243–51. doi: 10.1093/eurheartj/ehx760
25. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. (2013) 10:143–55. doi: 10.1038/nrcardio.2013.1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liang, Wang, Liu, Yu, Liang, Yin, Liu, Jiang, Wang, Bai, Liu, Shi, Li, Liu, Chen, Guo, Ma and Geng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.